



# Fertility Market Overview

Q3 2023


# The Appeal of the Fertility Services Industry

INVESTORS ARE HIGHLY INTERESTED IN THE FERTILITY SERVICES INDUSTRY DUE TO ITS LARGE SIZE, FRAGMENTATION, AND GROWTH OPPORTUNITIES.

- The U.S. fertility market is estimated to be \$10B+ across in-vitro fertilization (“IVF”), genetic testing, reproductive tissue storage, and donor services
  - Growing awareness of IVF and related services is creating an ever-larger addressable market opportunity; U.S. IVF services alone are estimated at nearly \$5B and projected to grow at a ~12%+ CAGR through 2025P
  
- Strong, long-term demand drivers include:
  - 1 Cultural shift to having children later in life, as well as lifestyle and health issues increasing incidences of infertility
  - 2 One of few healthcare service sectors in which clinical outcomes data are measured and reported, providing potential benefit to best-in-class providers
  - 3 Significant private pay component provides highly attractive reimbursement profile and insulation from pricing pressures relative to other healthcare sectors
  - 4 Highly recession-resistant demand due to parents’ desire to build families and the ticking of the biological clock
  
- Highly fragmented provider landscape primarily comprising local / regional clinics; platforms of scale are able to leverage best practices, invest in leading technology, attract new physician partners and scientists, and improve operations


## U.S. FERTILITY SERVICES MARKET<sup>(1)</sup>

(2023, \$ in billions)



## STRONG, RECESSION-RESISTANT DEMAND<sup>(3)</sup>

ART Cycles Performed in the U.S.



(1) HW internal estimates based on data from Allied Market Research, Cision PR Newswire, and Global Market Insights.  
 (2) Represents Prenatal and New-Born Genetic Testing market.

(3) CDC historical cycle data

# IVF vs. Other Fertility Treatment Methods

IVF IS ONE OF THE MOST SUCCESSFUL FERTILITY TREATMENTS AVAILABLE.<sup>(1)</sup>

- Most couples seeking fertility services explore multiple options with their physician, who develops a treatment plan that may consist of corrective surgery, natural cycle monitoring, ovulation induction, timed intercourse, IUI, and/or IVF
- IVF offers the highest success rates, a lower overall time to pregnancy, and greater applicability to a wider range of patients

In Vitro Fertilization (IVF)		Other Fertility Treatments																								
<b>Description</b>	<ul style="list-style-type: none"> <li>Involves fertilization of eggs in a laboratory setting after they have been removed from the ovaries</li> <li>Healthy embryo(s) is transferred back to the uterus to continue development</li> </ul>	<ul style="list-style-type: none"> <li>Relies on medication, intrauterine insemination (IUI), or corrective surgery (hysteroscopy, laparoscopy, myomectomy, etc.) to aid in conception</li> <li>Can sometimes be a first step, particularly among younger women, prior to IVF</li> </ul>																								
<b>Advantages</b>	<ul style="list-style-type: none"> <li>Greater control results in healthier babies and reduction in multiple births</li> <li>Addresses wide range of both male and female fertility issues, such as low sperm count and motility and damaged fallopian tubes</li> </ul>	<ul style="list-style-type: none"> <li>Typically less expensive than IVF</li> <li>Sometimes able to treat infertility less aggressively</li> </ul>																								
<b>Disadvantages</b>	<ul style="list-style-type: none"> <li>More expensive on a per treatment basis, but patients who seek IVF first can save thousands of dollars and more quickly achieve a successful birth</li> </ul>	<ul style="list-style-type: none"> <li>Often presents more risk than IVF, including higher chance of miscarriage, multiple births, and complications from surgery</li> <li>Several physical conditions, including abnormal fallopian tubes, make medication and injection treatments not possible for some patients facing infertility</li> </ul>																								
<b>Industry Average Cost<sup>(2)</sup></b>	<ul style="list-style-type: none"> <li>\$12,000 - \$25,000 per cycle (excluding medications, and assumes use of non-donor eggs on lower end); surrogacy can add \$60K-\$120K</li> </ul>	<ul style="list-style-type: none"> <li>Ranges from \$100 - \$5,000 per treatment</li> </ul>																								
<b>Industry Avg. Success Rates (Pregnancy Rate per Cycle)</b>	<p><b>Probability of Live Birth per IVF Cycle with Autologous Eggs<sup>(3)</sup></b></p> <table border="1"> <thead> <tr> <th>Age</th> <th>Probability of Live Birth per IVF Cycle with Autologous Eggs<sup>(3)</sup></th> </tr> </thead> <tbody> <tr> <td>&lt; 35</td> <td>54.5%</td> </tr> <tr> <td>35 - 37</td> <td>40.3%</td> </tr> <tr> <td>38 - 40</td> <td>25.9%</td> </tr> <tr> <td>41 - 42</td> <td>13.4%</td> </tr> <tr> <td>&gt; 42</td> <td>4.1%</td> </tr> </tbody> </table> <p>Women across all ages are over 3x more likely to conceive with IVF compared to other treatments</p>	Age	Probability of Live Birth per IVF Cycle with Autologous Eggs <sup>(3)</sup>	< 35	54.5%	35 - 37	40.3%	38 - 40	25.9%	41 - 42	13.4%	> 42	4.1%	<p><b>Probability of Pregnancy Using Medication and IUI<sup>(4)</sup></b></p> <table border="1"> <thead> <tr> <th>Age</th> <th>Probability of Pregnancy Using Medication and IUI<sup>(4)</sup></th> </tr> </thead> <tbody> <tr> <td>&lt; 35</td> <td>11.5%</td> </tr> <tr> <td>35 - 37</td> <td>9.2%</td> </tr> <tr> <td>38 - 40</td> <td>7.3%</td> </tr> <tr> <td>41 - 42</td> <td>4.3%</td> </tr> <tr> <td>&gt; 42</td> <td>1.0%</td> </tr> </tbody> </table>	Age	Probability of Pregnancy Using Medication and IUI <sup>(4)</sup>	< 35	11.5%	35 - 37	9.2%	38 - 40	7.3%	41 - 42	4.3%	> 42	1.0%
Age	Probability of Live Birth per IVF Cycle with Autologous Eggs <sup>(3)</sup>																									
< 35	54.5%																									
35 - 37	40.3%																									
38 - 40	25.9%																									
41 - 42	13.4%																									
> 42	4.1%																									
Age	Probability of Pregnancy Using Medication and IUI <sup>(4)</sup>																									
< 35	11.5%																									
35 - 37	9.2%																									
38 - 40	7.3%																									
41 - 42	4.3%																									
> 42	1.0%																									

(1) Yale Medicine.

(2) IBIS World Report on Fertility Clinics in the U.S., FertilityIQ, and Harris Williams proprietary data.


(3) Statistics based on publicly available SART data.

(4) Statistics based on study published by Serena Dovey in Fertility and Sterility and shown for females who took fertility medication in conjunction with receiving Intrauterine Insemination (IUI).

# IVF Treatment Overview

THE TYPICAL COST OF AN IVF CYCLE RANGES AS PATIENTS CHOOSE THE MOST APPROPRIATE COMBINATION OF SERVICES THAT INCREASES THEIR LIKELIHOOD OF A SUCCESSFUL PREGNANCY.

## TYPICAL IVF SERVICES COST BREAKOUT<sup>(1)</sup>



### Consultation

Individuals who try to conceive naturally may face difficulties due to age, health conditions, or other inhibiting factors, driving them to seek fertility treatment

- Potential patients are referred to consultation visits by other physicians, or through direct-to-consumer marketing efforts
- Physician practices perform consultations for patients
- Physician determines diagnosis and discusses goals/family planning with patients. Initial assessment may include carrier screening
- Physician develops treatment plan, which may include IVF initially or after other treatment options fail

### Fertility Medication

Often used in combination with other fertility treatments, including IUI and IVF

### IVF

Patients choose IVF for various reasons, including:

- Medical indications (e.g., blocked tubes, severe endometriosis, pelvic adhesions)
- Prior treatments were unsuccessful
- Screen familial genetic conditions or prior recurrent pregnancy loss (using PGT-M or PGT-A in conjunction with IVF)
- Option of using donor egg and/or donor sperm

If the patient proceeds with IVF, the physician will retrieve the patient's oocytes for assessment and will fertilize oocytes with sperm and culture the resulting embryos

### Preimplantation Genetic Testing

Screens for detectable genetic defects prior to selecting and transferring an embryo, which drives higher single embryo transfer and implantation rates

### Donor Services

Allows patients to utilize egg and/or sperm donors

### Fertility Storage/Egg Banking

Preservation of embryos, oocytes, sperm, and other reproductive tissue for future reproductive potential

# Strong Trends Driving Attractive Growth

FAVORABLE TRENDS WILL CONTINUE TO DRIVE STRONG GROWTH IN THE FERTILITY MARKET.

## INDUSTRY GROWTH DRIVERS

### INCREASING AWARENESS & ACCESSIBILITY

- Increasing awareness of fertility treatments as well as advancements in technology and genetic testing are increasing success rates and lowering total average costs to make treatment more accessible

### INCREASE IN CHRONIC HEALTH CONDITIONS

- Increasing prevalence of chronic conditions and health issues driving increasing rates of infertility and demand for IVF services

### CULTURAL SHIFTS

- Shifting cultural dynamics to have children later in life are driving people to use more IVF services as well as elective fertility preservation services
- Growing population of same-sex couples desiring children is driving additional demand


### REIMBURSEMENT & BENEFIT TRENDS

- Significant private pay component, despite moderately increasing insurance coverage and employee benefits for IVF and genetic testing services


## DRIVING SUSTAINED INDUSTRY GROWTH<sup>(1)</sup>

For the Years Ended and Ending December 31, 2017 – 2025P  
(\$ in billions)


### IVF SERVICES U.S. MARKET<sup>(2)</sup>



### GENETIC TESTING U.S. MARKET<sup>(2)(3)</sup>



### REPRODUCTIVE TISSUE STORAGE & DONOR SERVICES U.S. MARKET<sup>(2)</sup>



(1) Market size estimates were completed prior to the impact of COVID-19 in 2020 and do not reflect the brief pause in new cycle initiation experienced during the onset of the pandemic.  
 (2) HW internal estimates based on data from Allied Market Research, CDC, and Global Market Insights (all figures stated prior to the impact of COVID-19).  
 (3) Represents Prenatal and Newborn Genetic Testing market.

# Industry Growth Drivers: *Increasing Awareness and Accessibility*

THE INCREASING SOCIAL AWARENESS AND ACCESSIBILITY OF USING FERTILITY SERVICES, AS WELL AS PARENTS WAITING LONGER TO START A FAMILY, HAVE LED TO A RAPIDLY GROWING MARKET.

- Approximately eight million babies have been born globally using ART services since 1978<sup>(1)</sup>, driven by continued technological and genetic testing advancements and substantially improved outcomes and costs, resulting in increased accessibility and demand
- Rapidly growing social awareness of fertility services, such as high-profile references in popular culture and campaigns like the National Infertility Awareness Week
  - Driving greater interest in ART services, as demonstrated by an over 124% increase in ART cycles performed from 2010 to 2019<sup>(2)</sup>
- Since 1970, the average age of first motherhood in the U.S. has increased from 21 to 26, driven primarily by an increase in first children born to women 35 and older, with significantly increased infertility issues and demand for ART services among women in their 30s and 40s<sup>(3)</sup>

## GROWING CULTURAL AWARENESS

**BBC** Michelle Obama reveals daughters were conceived by IVF

**CNN** Dispelling taboos, Michelle Obama talks IVF and miscarriage

*"The biological clock is real and egg production is limited, something I realized at age 34; we had to do IVF. I think that as women the worst thing that we do to each other is that we do not share the truth about our bodies, how they work or do not work."*




- Michelle Obama


## INCREASED SUCCESS RATES DRIVE ACCESSIBILITY<sup>(4)</sup>

Overall improvement in IVF techniques has resulted in higher pregnancy rates per cycle, driving down the average total cost of an IVF pregnancy, making the service more accessible to a broader population


### Average Embryos Transferred with IVF



### Likelihood of a Live Birth by the Fifth Cycle with IVF




### Multiple Birth Rate with IVF



## ROOM TO GROW<sup>(5)</sup>

### IVF Prevalence by Country

IVF Cycle per 10,000 People



# Industry Growth Drivers: *Cultural Shifts*

SOCIETAL TRENDS HAVE RESULTED IN MORE COUPLES WHO REQUIRE FERTILITY SERVICES IN ORDER TO CONCEIVE.

## WOMEN DELAYING MOTHERHOOD DRIVE ART SERVICES


- Larger presence of women in the workforce and shift toward having children later in life have driven demand for ART services to increase chances of successful pregnancy later in life
  - Infertility and the probability of having children with genetic diseases increases as women age, driving increased demand for taking preventive measures with elective fertility preservation services and using ART services
- Organizations such as Single Mothers by Choice and Choice Mom have grown considerably in recent years
  - The growth of these organizations highlights the increasing number of women choosing to have children on their own, which typically requires ART services in order to conceive

## LARGE DEMAND FROM SAME-SEX COUPLES


- Cultural shifts and legislation changes have led to a growing number of same-sex couples having children
  - Approximately 16% of all same-sex households are raising children<sup>(1)</sup>
  - Growing number choosing to use ART services given the complexities of adoption

## U.S. BIRTH RATES BY AGE OF MOTHER<sup>(2)</sup>


Years Ended and Ending December 31, 1985-2020  
(Rate per Thousand Women Indexed at 100)



## SHARP DECREASE IN PROBABILITY OF CONCEIVING WITH AUTOLOGOUS EGGS BY AGE<sup>(3)</sup>



## GROWING POPULATION OF SAME-SEX COUPLES IN THE U.S.<sup>(4)</sup>




# Industry Growth Drivers: *Increase in Chronic Health Conditions*

~15% OF U.S. COUPLES ARE INVOLUNTARILY INFERTILE,<sup>(1)</sup> AND RISING OBESITY, MEDICAL CONDITIONS, AND OTHER FACTORS ARE DRIVING INFERTILITY RATES HIGHER, INCREASING DEMAND FOR FERTILITY SERVICES.

- Chronic health conditions present in males and females result in similar proportions of infertility cases in each gender
- Obesity is continuing to increase across the U.S. and is a large driver of infertility issues
  - Women defined as obese are three times more likely to suffer from infertility than women with a normal body mass index (BMI)
  - Polycystic Ovarian Syndrome (PCOS), a hormonal disorder that affects roughly 10% of women by interfering with ovulation patterns and drives infertility, is linked to obesity<sup>(2)</sup>
  - Likelihood of uterine abnormalities, including endometrial polyps, increases with age and obesity
  - Male obesity reduces sperm quality and impairs the molecular structure of mature sperm
- Both sexes are susceptible to decreasing fertility rates due to increased alcohol use, stress, and limited exercise
- Females in particular are susceptible to certain genetic and hormonal medical conditions that may interfere with reproductive abilities


## INFERTILITY CAUSES BY GENDER<sup>(3)</sup>

Percentage of Infertility Cases Attributed to Each Gender



## RISING OBESITY RATES<sup>(4)</sup>

Percentage of U.S. Population Defined as Obese



## MEDICAL CONDITIONS IMPACTING FERTILITY

### GENETIC CONDITIONS

- Birth Defects
- Chromosomal Abnormalities

### MEDICAL AND SURGICAL DISEASES

- Uterine Fibroids and Polyps (Benign Growths)
- Endometriosis (Pelvic Tissue Overgrowth)
- Autoimmune Disorders
- Early Menopause
- Obesity

### HORMONAL CONDITIONS

- PCOS
- Diabetes
- Thyroid Conditions

### OTHER FACTORS

- Sexually Transmitted Diseases
- Cancer / Chemotherapy
- Risk Factors (Age, Smoking, Alcohol, Stress, Limited Exercise)

# Industry Growth Drivers: *Reimbursement and Benefit Trends*


MORE ADULTS IN THE U.S. ARE GAINING ACCESS TO FERTILITY TREATMENTS DUE TO GROWING INSURANCE COVERAGE TRENDS AND FAVORABLE EMPLOYEE BENEFITS.

- Platforms of scale will comparatively benefit as coverage expands given their ability to drive better quality and negotiate higher reimbursement rates

## EMPLOYERS GAIN FROM OFFERING FERTILITY COVERAGE

- Attracts new talent in competitive job markets by providing cost-saving incentives and creating a “family-friendly” culture
- Greater fertility coverage allows employees to choose the safest fertility option and minimizes time away from work
  - IVF treatments lead to fewer complications due to lower chance of multiple births and low birthweight compared to other fertility treatments
    - Multiple births are associated with expensive complications including preterm birth, low birthweight, and high rates of disability
  - Alternative fertility treatments pose greater health risks and result in greater total expense burden placed on the employer
- Two-thirds of large employers already offer some level of fertility coverage

Average Costs Associated with Low Birthweight<sup>(1)</sup>  
(\$ in thousands)




## Select Companies Offering Fertility Benefits



## CHANGING REGULATIONS

- Since the 1980s, 19 states have passed laws that require employers’ insurers to either cover or offer some coverage for infertility diagnosis and/or treatment



- State Laws Requiring Insurance Companies to Cover Infertility Treatment
- State Laws Requiring Insurance Companies to Offer Coverage for Infertility Treatment

# Expansion of Fertility Benefits


EMPLOYERS INCREASINGLY RECOGNIZE THE VALUE CREATED FROM EXPANDED FERTILITY BENEFITS.

- In order to attract and retain talent, the number of employers that offer fertility benefits has doubled since 2018
- Expanding coverage creates direct-to-employer growth opportunity
- Superior clinical results create savings opportunities for self-insured employers that are continuing to expand fertility coverage
  - Produces fewer higher-order births relative to the industry, delivering significant incremental cost savings to payors/employers


## SURVEY DATA AROUND EMPLOYEES VALUING BENEFIT<sup>(1)</sup>

### Rapid Expansion of Corporate Fertility Benefits

~33% CAGR in Employers Offering Benefits




### Fertility Benefits Help Attract and Retain Talent



## SIGNIFICANT SAVINGS FROM TOP PROVIDERS

### Example of Potential Savings for IVF Deliveries for Payors per 1,000 Live Births<sup>(2)</sup>



Top Providers Offer Payors 15%+ Lower Pregnancy-Related Costs on Average per Live Birth Relative to the Industry



# Highly Fragmented Market


THE U.S. FERTILITY MARKET REMAINS HIGHLY FRAGMENTED AND MAINLY COMPRISES INDIVIDUAL CLINICS.

- The largest five players in the market capture only ~20% of the total IVF cycles in the U.S., representing a significant opportunity for existing players to expand national reach
- Significant opportunity to capitalize on international opportunity where few competitors of scale and quality exist


## HIGHLY FRAGMENTED MARKET

### U.S. Fertility Clinic Market by Cycles<sup>(1)</sup>

U.S. Fertility Clinic Market by 2019 Cycle Count




Fertility Clinics Segmented by Number of Cycles Performed



## COMPETITIVE LANDSCAPE

### Top U.S. IVF Clinics by Preliminary 2019 Cycle Count<sup>(1)</sup>




# Fertility Services and Women's Health M&A Activity

TRANSACTION ACTIVITY AND INTEREST IN FERTILITY AND BROADER WOMEN'S HEALTH SECTOR HAVE INCREASED DRAMATICALLY.

- Activity has been robust across all sectors of women's health, driven by continued demand growth industry-wide in fertility and the emergence of true value-based care models in OB/GYN
  - Fertility: Platform transformation continues with several large-scale platforms both in the U.S. and internationally reaching likely investment timeline maturity with current sponsors
  - OB/GYN: Unified, Women's Care Enterprises, and Axia have all experienced strong growth and recently partnered with new investors to continue their expansion

## NOTABLE TRANSACTIONS<sup>(1)</sup>



# M&A Observations and Outlook

DESPITE MORE CAUTIOUS SENTIMENT ACROSS THE M&A MARKET, FERTILITY REMAINS ONE OF THE BEST POSITIONED OF ALL HEALTHCARE SERVICES SECTORS AND INVESTOR INTEREST REMAINS HIGH.

## SECTOR POSITIONING VS. KEY INVESTOR EVALUATION CRITERIA

### WELL POSITIONED VS. INFLATION

- High degree of cash pay
- Scale and center of excellence providers drive better clinical outcomes and are highly important to payor / benefit manager networks
- Physicians typically paid on productivity, providing variable wage structure

### EXPOSURE TO ECONOMIC CYCLES

- Fertility care being among single most important life events meaningfully reduces exposure to economic downturns
- Limited ability or desire of patients to delay treatment
- Demonstrated highly recession resilient in 2008-2009

### ORGANIC GROWTH

- Among the fastest growing healthcare services sectors, with ~8-10% annual cycle expansion
- Meaningful secular tailwinds and growing access expected to drive growth for decades

### PLATFORMS DRIVE MEANINGFUL BENEFITS FOR PHYSICIANS






- Ability to cost-efficiently roll out ancillaries and participate in economics
- Opportunity to participate in broader scientific / physician community
- Enhanced patient marketing and referral capture

# Select Harris Williams Fertility Transaction Advisory

HARRIS WILLIAMS IS THE LEADING ADVISOR IN THE FERTILITY SECTOR WITH NEARLY A DECADE OF EXPERIENCE EXECUTING HIGHLY SUCCESSFUL TRANSACTIONS.

- Advisory experience spans full breadth of sector including reproductive tissue, IVF clinic, fertility benefit management, pharmacy, and donor/storage
- Unique insights into both strategic and financial buyers most interested in sector as well as key value drivers informing investment decisions

  
a portfolio company of  
  
has merged with  
  
a portfolio company of  


  
a portfolio company of  
  
has established a strategic partnership with  
  
a portfolio company of  
 

  
a portfolio company of  
  
has been recapitalized by  


  
has acquired and merged  
  
and  


  
a portfolio company of  
  
  
has acquired  


  
a portfolio company of  
  
  
has acquired  



# Key Investor Focus Areas

HARRIS WILLIAMS HAS A DEEP UNDERSTANDING OF KEY VALUE DRIVERS THAT BUYERS ARE LOOKING FOR WITHIN THE FERTILITY SECTOR, INFORMED BY RECENT TRANSACTION ADVISORY EXPERIENCE.

**Please contact HW for additional information**

# Fertility Market Landscape

WITH INCREASING INVESTMENT IN THE SECTOR, A NUMBER OF SCALED FERTILITY PLATFORMS HAVE EMERGED IN THE U.S., EUROPE, AND PARTS OF ASIA.



# A Collaborative Approach to Consumer Healthcare

WE POOL THE EXPERTISE IN CONSUMER AND HEALTHCARE AND LIFE SCIENCES TO ADVISE PREMIER COMPANIES ACROSS THE CONSUMER HEALTHCARE LANDSCAPE.

FOR MORE INFORMATION ON OUR EXPERIENCE IN THE FERTILITY SECTOR, CONTACT ANDY DIXON:



**Andy Dixon**  
 Managing Director  
 Healthcare & Life Sciences Group  
[adixon@harriswilliams.com](mailto:adixon@harriswilliams.com)  
 +1 415.217.3419



**Geoff Smith**  
 Managing Director and Co-Head  
 Healthcare & Life Sciences Group  
[gsmith@harriswilliams.com](mailto:gsmith@harriswilliams.com)  
 +1 804.915.0195



**Corey Benjamin**  
 Managing Director  
 Consumer Group  
[cbenjamin@harriswilliams.com](mailto:cbenjamin@harriswilliams.com)  
 +1 804.932.1342



**Whit Knier**  
 Managing Director  
 Healthcare & Life Sciences Group  
[wknier@harriswilliams.com](mailto:wknier@harriswilliams.com)  
 +1 804.887.6021

## SELECT RECENT TRANSACTIONS

 a portfolio company of Morgan Stanley CAPITAL PARTNERS has merged with  a portfolio company of 	 a portfolio company of Audax Private Equity has been acquired by Loblaw Companies Limited on behalf of its wholly owned subsidiary 	 a portfolio company of  has been acquired by 	 a portfolio company of LIGHTBAY CAPITAL has been acquired by 
---	---	--	--

Fertility

Physical Therapy

Dermatology

Veterinary

 a portfolio company of TA ASSOCIATES has established a strategic partnership with  a portfolio company of ALTAS PARTNERS 	 a portfolio company of JLL Partners has been acquired by HEARTLAND a portfolio company of 	 has received an investment from 	 a portfolio company of Baird Capital has been acquired by 
---	---	--	---

Fertility

Dental

Vision

Behavioral



**Dan Linsalata**  
 Managing Director  
 Healthcare & Life Sciences Group  
[dlinsalata@harriswilliams.com](mailto:dlinsalata@harriswilliams.com)  
 +1 617.654.2122



**Nate Robertson**  
 Director  
 Healthcare & Life Sciences Group  
[nrobertson@harriswilliams.com](mailto:nrobertson@harriswilliams.com)  
 +1 804.887.6135

# HW Harris Williams / GLOBAL M&A ADVISOR

Harris Williams is a global investment bank specializing in M&A advisory services. Clients worldwide rely on us to help unlock value in their business and turn ambitious goals into reality. We approach every engagement with boundless collaboration, pooling expertise and relationships across industries and geographies to uncover the unique story of each company.

## Deep Industry Experience



Aerospace, Defense & Government Services



Business Services



Consumer



Energy, Power & Infrastructure



Healthcare & Life Sciences



Industrials



Technology



Transportation & Logistics

70% Revenue from repeat clients

83% Managing directors promoted from within the firm

30+ Year history



# Disclosures

Investment banking services are provided by Harris Williams LLC (“Harris Williams”). Harris Williams is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8thFloor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales (registration number 07078852). Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is BockenheimerLandstrasse33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com). Geschäftsführer/Directors: Jeffery H. Perkins, Paul Poggi. (VAT No. DE321666994). Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.

The information and views contained in this presentation have been prepared in part by Harris Williams. This presentation does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate any investment or potential transaction. This presentation is not a research report, as such term is defined by applicable law and regulations, and is provided for informational purposes only. Any and all information, including estimates, projections and other forward-looking statements, presented in this document may involve various assumptions and significant elements of subjective judgment and analysis which may or may not be correct. Harris Williams has not independently verified, and neither Harris Williams nor any other person will independently verify, any of the information, estimates, projections or forward-looking statements contained herein or the assumptions on which they are based. The information contained in this document is made as of the date hereof unless stated otherwise. Harris Williams does not expect to update or otherwise revise this document nor provide any additional information, nor correct any inaccuracies herein which may become apparent.

The information contained herein is believed by Harris Williams to be reliable but Harris Williams makes no representation or warranty as to the accuracy or completeness of such information, and information contained herein that is based on material prepared by others may involve significant elements of subjective judgment and analysis which may or may not be correct. Opinions estimates and projections in this presentation constitute Harris Williams’ judgment and are subject to change without notice.

This presentation is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular transaction, nor shall this presentation form the basis of any contract. It does not constitute and should not be construed as an endorsement or recommendation of any entities’ products or services.

No part of this material may be copied or duplicated in any form or by any means, or redistributed, without Harris Williams’ prior written consent.